Arch Pathol Lab News Today

Results presented at AACR 2023 found that four times as many patients treated with Imfinzi plus chemotherapy before surgery achieved pathologic complete response versus those treated with neoadjuvant... | April 16, 2023

NASHVILLE and PHILADELPHIA (PRWEB) March 01, 2023 -- Proscia®, a leading provider of digital and computational pathology solutions, today announced

Approval based on DESTINY-Breast04 results where Daiichi Sankyo and AstraZeneca's ENHERTU reduced the risk of disease progression or death by 50% and increased median overall survival by more than

AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been approved in the European Union (EU) as monotherapy for the treatment of adult patients with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer who have received prior chemotherapy in the metastatic setting or developed ...

/PRNewswire/ -- Ibex Medical Analytics (Ibex), the leader in AI-powered cancer diagnostics, today announced an agreement with AstraZeneca and Daiichi Sankyo,...

Enhertu Approved by Health Canada as the First HER2-Directed Therapy for Patients with HER2-Low Metastatic Breast Cancer - read this article along with other careers information, tips and advice on BioSpace

Investegate announcements from AstraZeneca PLC, Enhertu recommended for EU approval in HER2-low BC

Recent work has demonstrated the possibility of using a flexible, ultra-thin holographic endoscope for the microscopic imaging of tissues using an approach known as lensless Fourier holographic imaging.

DESTINY-Lung02 phase 2 trial shows clinically meaningful efficacy and favorable safety at 5.4 mg/kg dose versus 6.4 mg/kg dose of Daiichi Sankyo and A

Investegate announcements from AstraZeneca PLC, Enhertu granted Priority Review for HER2-low mBC